Acquisition History / Tokuyama Corporation / JSR Corporation in-vitro diagnostics business
Tokuyama Corporation Acquires JSR Corporation in-vitro diagnostics business
Announced April 24, 2025 — $549.4M
What happened
Tokuyama agreed to acquire JSR's in-vitro diagnostics business, which will be transferred into a new company whose shares Tokuyama buys in full on 1 October 2025. The immunoassay reagent and particle technology strengthens Tokuyama's health care segment alongside its diagnostics subsidiary A&T.
- Acquirer
- Tokuyama Corporation
- Target
- JSR Corporation in-vitro diagnostics business
- Announced
- April 24, 2025
- Price
- $549.4M
- Industry
- In-vitro diagnostics
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Tokuyama Corporation acquire JSR Corporation in-vitro diagnostics business?
Tokuyama Corporation acquired JSR Corporation in-vitro diagnostics business on April 24, 2025. This was Tokuyama Corporation's 1st publicly tracked acquisition out of 1 we have on record.
How much did Tokuyama Corporation pay for JSR Corporation in-vitro diagnostics business?
Tokuyama Corporation paid $549.4M for JSR Corporation in-vitro diagnostics business.
What does JSR Corporation in-vitro diagnostics business do?
Tokuyama agreed to acquire JSR's in-vitro diagnostics business, which will be transferred into a new company whose shares Tokuyama buys in full on 1 October 2025. The immunoassay reagent and particle technology strengthens Tokuyama's health care segment alongside its diagnostics subsidiary A&T.
What other In-vitro diagnostics companies has Tokuyama Corporation acquired?
JSR Corporation in-vitro diagnostics business is Tokuyama Corporation's only publicly tracked acquisition in In-vitro diagnostics so far.